Loading...
XMEXLABB
Market cap1.22bUSD
Dec 20, Last price  
25.78MXN
1D
0.82%
1Q
23.94%
Jan 2017
19.80%
IPO
211.92%
Name

Genomma Lab Internacional SAB de CV

Chart & Performance

D1W1MN
XMEX:LABB chart
P/E
22.53
P/S
1.48
EPS
1.14
Div Yield, %
2.38%
Shrs. gr., 5y
-1.33%
Rev. gr., 5y
6.90%
Revenues
16.47b
-2.10%
692,666,0001,373,480,0001,872,863,0002,629,430,0004,424,655,0006,263,621,0008,074,787,0009,799,690,00011,360,689,00011,540,998,00011,042,452,00011,316,310,00012,078,443,00011,794,419,00012,712,890,00013,870,148,00015,487,059,00016,819,912,00016,467,126,000
Net income
1.08b
-21.90%
-114,344,000180,301,000304,399,000515,776,000760,036,0001,092,958,0001,415,954,0001,504,004,0001,760,607,0001,444,558,000-1,068,519,000-1,680,925,0001,279,208,0001,109,465,000764,463,0001,403,503,0001,307,867,0001,389,203,0001,084,915,000
CFO
2.25b
+9.35%
-101,407,000103,331,000228,892,000385,519,000849,667,00089,212,000-107,086,0001,870,747,0001,038,596,000322,300,0001,674,845,0001,420,074,0001,562,479,0001,006,931,0001,714,525,0001,468,351,0002,054,793,0002,247,012,000
Dividend
Sep 13, 20240.2 MXN/sh
Earnings
Feb 19, 2025

Profile

Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico and internationally. It provides skin care, health and wellness, hair care, pain relief, cough and cold, gastro, sexual health, antiperspirant deodorant, hand sanitizer, isotonic deink, and razor products, as well as analgesics, antifungals, and hemorrhoids. The company offers its products under the Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, and other brands. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.
URL
http://www.genommalab.com/mx/
IPO date
Jun 19, 2008
Employees
2,388
Domiciled in
MX
Incorporated in
MX

Valuation

Title
MXN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
16,467,126
-2.10%
16,819,912
8.61%
15,487,059
11.66%
Cost of revenue
13,222,085
13,578,678
12,494,170
Unusual Expense (Income)
NOPBT
3,245,041
3,241,234
2,992,889
NOPBT Margin
19.71%
19.27%
19.33%
Operating Taxes
635,674
867,609
914,010
Tax Rate
19.59%
26.77%
30.54%
NOPAT
2,609,367
2,373,625
2,078,879
Net income
1,084,915
-21.90%
1,389,203
6.22%
1,307,867
-6.81%
Dividends
(580,704)
(777,663)
(391,756)
Dividend yield
4.29%
4.64%
1.81%
Proceeds from repurchase of equity
(162,266)
(523,774)
(78,905)
BB yield
1.20%
3.13%
0.36%
Debt
Debt current
2,005,294
4,851,497
2,105,127
Long-term debt
4,280,974
1,653,390
3,912,285
Deferred revenue
Other long-term liabilities
114,495
115,077
489,144
Net debt
4,085,019
4,220,579
4,031,507
Cash flow
Cash from operating activities
2,247,012
2,054,793
1,468,351
CAPEX
(19,473)
(206,579)
Cash from investing activities
(302,210)
(282,297)
(765,616)
Cash from financing activities
(1,676,821)
(1,362,397)
(1,469,237)
FCF
(3,103,113)
1,715,236
2,096,028
Balance
Cash
1,655,328
1,496,556
1,220,905
Long term investments
545,921
787,752
765,000
Excess cash
1,377,893
1,443,312
1,211,552
Stockholders' equity
12,687,251
11,958,795
11,331,922
Invested Capital
14,417,174
14,229,327
14,062,768
ROIC
18.22%
16.78%
15.01%
ROCE
20.13%
20.18%
18.91%
EV
Common stock shares outstanding
957,344
993,229
1,007,626
Price
14.14
-16.18%
16.87
-21.46%
21.48
14.01%
Market cap
13,536,844
-19.21%
16,755,773
-22.58%
21,643,806
13.54%
EV
17,621,863
20,976,352
25,675,313
EBITDA
3,472,344
3,468,359
3,163,155
EV/EBITDA
5.07
6.05
8.12
Interest
829,903
525,641
444,390
Interest/NOPBT
25.57%
16.22%
14.85%